Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

AFMD

Affimed NV (AFMD)

Affimed NV

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:AFMD

1 2 3 4 5 6 7 8 9 10 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
24/04/2024	10h05	GlobeNewswire Inc.	Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	NASDAQ:AFMD	Affimed NV
28/03/2024	11h30	GlobeNewswire Inc.	Affimed Reports 2023 Financial Results and Operational Progress	NASDAQ:AFMD	Affimed NV
21/03/2024	11h30	GlobeNewswire Inc.	Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	NASDAQ:AFMD	Affimed NV
11/03/2024	21h05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
06/03/2024	12h30	GlobeNewswire Inc.	Affimed Announces 1-for-10 Reverse Stock Split	NASDAQ:AFMD	Affimed NV
08/01/2024	22h05	GlobeNewswire Inc.	Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	NASDAQ:AFMD	Affimed NV
08/01/2024	14h00	GlobeNewswire Inc.	Affimed Announces Leadership Change and Organizational Restructuring	NASDAQ:AFMD	Affimed NV
03/01/2024	12h30	GlobeNewswire Inc.	Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck	NASDAQ:AFMD	Affimed NV
11/12/2023	12h02	GlobeNewswire Inc.	Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients	NASDAQ:AFMD	Affimed NV
11/12/2023	12h00	GlobeNewswire Inc.	Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)	NASDAQ:AFMD	Affimed NV
04/12/2023	12h30	GlobeNewswire Inc.	Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24	NASDAQ:AFMD	Affimed NV
14/11/2023	12h30	GlobeNewswire Inc.	Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	NASDAQ:AFMD	Affimed NV
09/11/2023	12h30	GlobeNewswire Inc.	Affimed Announces Acimtamig as International Nonproprietary Name for AFM13	NASDAQ:AFMD	Affimed NV
07/11/2023	12h30	GlobeNewswire Inc.	Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023	NASDAQ:AFMD	Affimed NV
03/11/2023	17h05	GlobeNewswire Inc.	Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	NASDAQ:AFMD	Affimed NV
02/11/2023	14h05	GlobeNewswire Inc.	Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting	NASDAQ:AFMD	Affimed NV
01/11/2023	11h30	GlobeNewswire Inc.	Affimed to Participate in Upcoming Investor Conferences	NASDAQ:AFMD	Affimed NV
04/10/2023	12h30	GlobeNewswire Inc.	Affimed Announces Listing Transfer to Nasdaq Capital Markets	NASDAQ:AFMD	Affimed NV
27/09/2023	15h05	GlobeNewswire Inc.	Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	NASDAQ:AFMD	Affimed NV
21/09/2023	12h30	GlobeNewswire Inc.	Affimed to Present at the Cantor Global Healthcare Conference 2023	NASDAQ:AFMD	Affimed NV
12/09/2023	12h30	GlobeNewswire Inc.	Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma	NASDAQ:AFMD	Affimed NV
07/09/2023	12h30	GlobeNewswire Inc.	Affimed to Present at the H.C. Wainwright Annual Global Investment Conference	NASDAQ:AFMD	Affimed NV
22/08/2023	11h00	GlobeNewswire Inc.	Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability	NASDAQ:AFMD	Affimed NV
10/08/2023	12h30	GlobeNewswire Inc.	Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress	NASDAQ:AFMD	Affimed NV
03/08/2023	12h30	GlobeNewswire Inc.	Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023	NASDAQ:AFMD	Affimed NV
31/07/2023	23h05	GlobeNewswire Inc.	Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells	NASDAQ:AFMD	Affimed NV
22/06/2023	12h30	GlobeNewswire Inc.	Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board	NASDAQ:AFMD	Affimed NV
09/06/2023	23h59	GlobeNewswire Inc.	Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)	NASDAQ:AFMD	Affimed NV
05/06/2023	12h06	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AFMD	Affimed NV
03/06/2023	15h00	GlobeNewswire Inc.	Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan	NASDAQ:AFMD	Affimed NV

Showing the most relevant articles for your search:NASDAQ:AFMD

1 2 3 4 5 6 7 8 9 10 Suivant >>

Societe Generale

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales